T Cell

T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.

Adoptive T Cell Therapy Methodology

Adoptive T cell therapy is a type of immunotherapy that has the ability to target cancer cells through inherent mechanisms of the immune system.

Adoptive T Cell Therapy Applications

T-Cell Metabolism, Immunodeficiency and Human Disease

CAR-T Cell Toxicity and Safety Profiles

Inherited genetics can influence safety and success of CAR-T cell therapy

Chimeric antigen receptor (CAR)-T cell therapy, which reprograms an individual's immune cells to seek out and destroy certain cancer cells, has revolutionized treatment for blood cancers such as lymphoma.

24 Jul 2026

Spermidine boosts key cellular processes linked to aging in early research

This review finds that spermidine supports autophagy, mitochondrial function, and healthspan in experimental models, while observational studies link higher dietary intake to lower mortality. However, human trials have produced limited and mixed results, leaving its clinical role in healthy aging unresolved.

23 Jul 2026

Thymulin curbs age-related inflammation and slows breast tumors in mice

Thymulin reduced age-associated inflammatory myeloid cells and slowed breast-tumor growth in aged mice by suppressing NF-κB signaling. The peptide also restored anti-PD-L1 responsiveness in aged mouse models, while human cell and tumor data supported an age-linked inflammatory myeloid profile.

23 Jul 2026

New study redefines high risk criteria for multiple myeloma

Researchers have found that with new treatments for multiple myeloma, a serious type of blood cancer, clinicians should use different criteria for identifying patients with poor odds of survival.

20 Jul 2026

Study identifies immune response causing severe COVID-19 susceptibility

Although the COVID-19 pandemic has largely subsided, scientists continue to investigate why the virus proved so deadly, causing at least three million deaths worldwide, according to the latest estimates by the World Health Organization (WHO).

19 Jul 2026

KAIST study opens a new avenue for treating intractable brain tumors

Researchers have uncovered a clue to why immune checkpoint inhibitors-cancer therapies that release the immune "brakes" exploited by tumors to evade attack-show limited efficacy in some brain tumors.

19 Jul 2026

Targeting ZBP1 may overcome cancer immunotherapy resistance

A new Review published in the open-access journal Ferroptosis and Oxidative Stress highlights Z-nucleic acid-binding protein 1 (ZBP1) as an emerging innate immune sensor that converts genomic stress into potent antitumor immunity.

16 Jul 2026

Experimental KRAS vaccine safely generates durable immune response against pancreatic cancer

Researchers at the Johns Hopkins Kimmel Cancer Center and its Skip Viragh Center for Pancreatic Cancer report that an experimental vaccine targeting mutant KRAS, one of the most common genetic drivers of pancreatic cancer, was safe and generated durable immune responses aimed at preventing the cancer in people at high risk.

16 Jul 2026

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

Evaxion A/S (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.

14 Jul 2026

Cold-exposed mothers pass metabolic protection to male rat offspring through milk

Maternal cold exposure during early pregnancy improved glucose control and reduced liver fat in male rat offspring, with benefits persisting into late adulthood. The findings implicate a breast milk LCA, gut microbiota, and Th17 immune pathway, while human cohort data showed an observational link between winter conception and lower MASLD risk.

12 Jul 2026

Off-the-shelf CAR T therapy targets treatment-resistant systemic sclerosis

Today at ISSCR 2026, new preliminary clinical data was presented evaluating an induced pluripotent stem cell (iPSC)-derived CAR T-cell therapy for patients with treatment-resistant systemic sclerosis, a rare autoimmune disease with high mortality.

9 Jul 2026

Discovery could pave the way for future vaccines against genital herpes

Researchers at the University of Gothenburg have identified a key protein that allows the virus that causes genital herpes to get into the nervous system.

9 Jul 2026

Novel leukemia therapy successfully eradicates measurable residual disease

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

7 Jul 2026

New analysis reveals biological features of treatment-resistant aggressive lymphoma

Researchers led by Universitätsmedizin Frankfurt and Goethe University Frankfurt have identified how particularly aggressive forms of lymphoma can be recognized.

3 Jul 2026

Feeder-free TIL expansion system makes advanced cancer immunotherapy safer

Conventional TIL therapy, clinically validatedrecently with the U.S. Food and Drug Administration approval of lifileucel for advanced melanoma,stillfaces substantial hurdles.

3 Jul 2026

Engineered CAR T cells show promise against myeloproliferative neoplasms

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, in new research led by UCL and University of Oxford researchers.

1 Jul 2026

New bacterial enzyme blueprint could accelerate cancer treatment development

A team of researchers at the University of Warwick and Monash University has solved a puzzle that's stumped drug developers for decades: how bacteria naturally create multiple versions of powerful cancer therapies.

1 Jul 2026

New AI framework outperforms conventional biomarkers in predicting cancer survival

Digestive system cancers, including hepatobiliary and gastrointestinal malignancies, remain a major global oncological burden. Although immune checkpoint inhibitors have changed the treatment landscape for some patients, their overall efficacy remains limited, with only about 15% to 30% of patients achieving durable clinical benefit.

1 Jul 2026

Dual-target CAR-T therapy shows promise against aggressive brain tumors

Researchers at McMaster University have developed a new cancer immunotherapy strategy that can simultaneously attack deadly brain tumors and the immune cells that help them grow.

1 Jul 2026

Probiotic metabolite found to suppress melanoma tumor growth in mice

Immune checkpoint inhibitors like anti-PD-1 have transformed melanoma treatment, yet more than half of patients fail to respond or eventually develop resistance.

30 Jun 2026